Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCTX BriaCell Therapeutics	$3.41 +4.6%	$3.87	$2.81 ▼ $29.40	$12.74M	1.38	541,132 shs	125,964 shs
CSCI COSCIENS Biopharma	$3.82 +12.0%	$3.19	$1.96 ▼ $6.77	$12.02M	0.89	12,223 shs	3,375 shs
HOTH Hoth Therapeutics	$0.85 -2.5%	$0.87	$0.58 ▼ $3.80	$11.18M	0.53	3.47 million shs	18,790 shs
WINT Windtree Therapeutics	$0.80 +0.6%	$1.10	$0.73 ▼ $737.44	$2.91M	0.82	750,704 shs	34,206 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCTX BriaCell Therapeutics	+2.84%	-4.40%	-28.98%	-11.17%	-85.89%
CSCI COSCIENS Biopharma	+0.29%	-1.02%	-1.13%	+24.03%	+350,999,900.00%
HOTH Hoth Therapeutics	+2.36%	+3.30%	+1.92%	-5.30%	-24.58%
WINT Windtree Therapeutics	-5.95%	+5.60%	-30.09%	-75.16%	-99.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCTX BriaCell Therapeutics	2.5509 of 5 stars	3.5	5.0	0.0	0.0	2.1	0.0	0.6
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	2.7457 of 5 stars	3.6	3.0	0.0	0.0	2.4	0.8	1.3
WINT Windtree Therapeutics	1.6017 of 5 stars	3.0	2.0	0.0	0.0	1.9	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCTX BriaCell Therapeutics	3.00	Buy	$32.00	838.14% Upside
CSCI COSCIENS Biopharma	0.00	N/A	N/A	N/A
HOTH Hoth Therapeutics	3.25	Buy	$4.00	372.81% Upside
WINT Windtree Therapeutics	2.00	Hold	$350.00	43,925.16% Upside

Current Analyst Ratings Breakdown

Latest WINT, BCTX, HOTH, and CSCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2025	BCTX BriaCell Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/15/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/31/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/10/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/4/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCTX BriaCell Therapeutics	N/A	N/A	N/A	N/A	($2.20) per share	N/A
CSCI COSCIENS Biopharma	$9.03M	1.33	N/A	N/A	$14.99 per share	0.25
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$2.03 per share	N/A
WINT Windtree Therapeutics	N/A	N/A	N/A	N/A	$10.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCTX BriaCell Therapeutics	-$4.79M	-$5.03	N/A	N/A	N/A	N/A	N/A	-191.19%	6/13/2025 (Estimated)
CSCI COSCIENS Biopharma	-$16.55M	-$5.80	N/A	∞	N/A	-428.43%	-95.93%	-45.66%	8/11/2025 (Estimated)
HOTH Hoth Therapeutics	-$7.84M	-$1.14	N/A	N/A	N/A	N/A	-89.68%	-82.61%	8/8/2025 (Estimated)
WINT Windtree Therapeutics	-$20.29M	-$823.47	N/A	N/A	N/A	N/A	-362.76%	-79.65%	8/18/2025 (Estimated)

Latest WINT, BCTX, HOTH, and CSCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/13/2025	N/A	BCTX BriaCell Therapeutics	-$1.76	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	WINT Windtree Therapeutics	-$39.00	-$4.63	+$34.37	-$4.63	$2.20 million	N/A
5/13/2025	Q1 2025	CSCI COSCIENS Biopharma	N/A	-$1.16	N/A	-$1.16	N/A	$1.50 million
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A
4/9/2025	Q4 2024	CSCI COSCIENS Biopharma	-$3.48	-$2.15	+$1.33	-$2.15	$1.10 million	$3.32 million
3/27/2025	Q4 2024	HOTH Hoth Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	N/A	N/A
3/17/2025	Q2 2025	BCTX BriaCell Therapeutics	-$1.94	-$2.33	-$0.39	-$2.33	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCTX BriaCell Therapeutics	N/A	N/A	N/A	N/A	N/A
CSCI COSCIENS Biopharma	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
WINT Windtree Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCTX BriaCell Therapeutics	N/A	1.65	1.65
CSCI COSCIENS Biopharma	N/A	3.46	3.05
HOTH Hoth Therapeutics	N/A	10.17	10.17
WINT Windtree Therapeutics	N/A	0.27	0.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCTX BriaCell Therapeutics	15.42%
CSCI COSCIENS Biopharma	0.73%
HOTH Hoth Therapeutics	7.08%
WINT Windtree Therapeutics	29.33%

Insider Ownership

Company	Insider Ownership
BCTX BriaCell Therapeutics	5.73%
CSCI COSCIENS Biopharma	0.10%
HOTH Hoth Therapeutics	10.56%
WINT Windtree Therapeutics	0.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCTX BriaCell Therapeutics	8	3.71 million	3.50 million	Optionable
CSCI COSCIENS Biopharma	20	3.15 million	3.77 million	N/A
HOTH Hoth Therapeutics	4	13.21 million	6.18 million	Not Optionable
WINT Windtree Therapeutics	30	3.66 million	11.01 million	Not Optionable

WINT, BCTX, HOTH, and CSCI Headlines

Recent News About These Companies

Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Increases By 110.2%

May 30 at 1:27 AM | americanbankingnews.com

WINT stock touches 52-week low at $0.75 amid steep annual decline

May 24, 2025 | uk.investing.com

Windtree Therapeutics Advances Istaroxime Cardiogenic Shock Program with SEISMiC C Study Interim Analysis Planned for July 2025

May 22, 2025 | quiverquant.com

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

May 22, 2025 | globenewswire.com

Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference

May 19, 2025 | manilatimes.net

Windtree Therapeutics to Present Istaroxime Data at European Society of Cardiology Heart Failure 2025 Conference

May 19, 2025 | quiverquant.com

Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates

May 16, 2025 | finanznachrichten.de

Windtree Therapeutics announces resale of 42.17M shares by selling stockholders

May 16, 2025 | msn.com

Windtree Therapeutics Announces Positive Results on Istaroxime and SERCA2a Activator in Reducing Arrhythmias at ESC Heart Failure Congress

May 13, 2025 | nasdaq.com

Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

May 12, 2025 | globenewswire.com

Windtree Therapeutics Unveils U.S. Exclusivity Strategy for Istaroxime

May 10, 2025 | msn.com

Windtree Therapeutics Announces Strategic Pathway for 7.5 Years of U.S. Exclusivity for Istaroxime in Cardiogenic Shock

May 8, 2025 | nasdaq.com

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

May 6, 2025 | globenewswire.com

Biotech Company Jumps Into Houston Multifamily In Quest For Revenue Amid Stock Slide

May 5, 2025 | bisnow.com

Why biotech firm Windtree Therapeutics is buying a 436-unit apartment complex

May 5, 2025 | bizjournals.com

Windtree Therapeutics Announces Plans to Acquire Multifamily Residential Property

May 5, 2025 | msn.com

Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development

May 1, 2025 | finance.yahoo.com

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

April 15, 2025 | markets.businessinsider.com

Evofem announces license and supply agreement with Windtree Therapeutics

March 27, 2025 | markets.businessinsider.com

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

March 26, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

WINT, BCTX, HOTH, and CSCI Company Descriptions

BriaCell Therapeutics NASDAQ:BCTX

$3.41 +0.15 (+4.63%)

As of 12:01 PM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

COSCIENS Biopharma NASDAQ:CSCI

$3.82 +0.41 (+12.02%)

As of 11:33 AM Eastern

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Hoth Therapeutics NASDAQ:HOTH

$0.85 -0.02 (-2.46%)

As of 11:59 AM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Windtree Therapeutics NASDAQ:WINT

$0.80 +0.01 (+0.63%)

As of 12:02 PM Eastern

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time